Pharmathen was founded in 1969 in Athens, as a private pharmaceutical company, and is focused on the development and marketing of pharmaceuticals, with a strong position in generics. With 3 state of the art research laboratories and 2 manufacturing units, Pharmathen is a backwardly vertically integrated company and its activities extend from the development of pharmaceutical products up to their distribution.
The company’s human resources include more than 1050 people who work in the sectors of Research & Development (R&D), production and distribution of drugs to more than 85 countries worldwide. Today, Pharmathen’s products are approved in all EU markets and distribution rights have been granted to the largest pharmaceutical companies in the world, particularly in Europe, the United States of America and Canada. Sales of Pharmathen products reached a total of €181 million in 2014.
Sustained Release Parenteral Depots – Long Acting Injectables
Pharmathen through its accumulated experience and know-how, is also able to provide, apart from products and advance technological solutions, various independent services to its partners, which are vital to the pharmaceutical industry worldwide. These services, which include: Medical & Pharmacovigilance, Third Party Auditing, Regulatory Affairs, Quality Management & Quality Assurance, Quality Control, Intellectual Property, and Scientific Operations.
Pharmathen is a research-oriented company aiming at the development of high quality pharmaceutical products both in the field of generics and innovative finished formulations. With the application of innovative techniques and advanced technologies, Pharmathen aims to provide challenging solutions LCM of brand companies as well as to develop and establish new technology platforms and provide optimized pharmaceutical products to patients. These activities are supported by two autonomous advanced laboratories in a 1200 m2 building in Pallini/Athens hosting a GLP/GMP compliant environment where lab-scale and pilot-scale development are conducted.
The intense R&D activity has resulted in Intellectual Property that in all cases is protected by patents (granted by European Patent Office, EPO and the United States Patent and Trademark Office, USPTO) and patent applications (PCT applications). Pharmathen R&D Dpt. is also actively involved in a number of research projects in collaboration with renowned Universities and Research Centers across the E.U., in order to investigate advanced and pioneering pharmaceutical technologies as well as their application on an industrial scale.
Pharmathen’s R&D activities have been vertically intergraded including Research and Development of Active Pharmaceutical Ingredients (APIs). The APIs operations are supported by the API Research and Development Centre located in Thessaloniki, Greece, and a second API Research and Development Centre in Vadodara, India.
Clients & Collaborations (NATIONAL)
Pharmathen is in close collaboration with universities and research institutes through its participation in national and international research projects. So far, Pharmathen has established collaborations with the following institutions:
Biomedical Sciences Research Center “Alexander Fleming”
National Center for Scientific Research “Demokritos”
Centre for Research and Technology – Thessaly
Academy of Athens, Medical and Biological Research Foundation
National and Kapodistrian University of Athens
Aristotle University of Thessaloniki
Agricultural University of Athens
University of Patras
Demokritus University of Thrace, Alexandroupoli
Clients & Collaborations (INTERNATIONAL)
Pharmathen is already in partnership with more than 170 companies in Europe and Canada, including among them the leading pharmaceutical companies in a national and European level, such as Sanofi, Novartis, Merck, Actavis, Ratiopharm, Teva, Mylan, Sandoz, Stada, Ranbaxy and many others.